Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating

Minmin Xu1, Li Ren1, Jinhua Fan1

  • 1Engineering Research Center of Coptis Development & Utilization (Ministry of Education), School of Life Sciences, Southwest University, Chongqing 400715, China.

Life Sciences
|December 30, 2021
PubMed
Abstract

Insights

Berberine (BBR) effectively inhibits gastric cancer (GC) cell proliferation, migration, and invasion. This natural compound shows promise for gastric cancer prevention by targeting the IL-6/JAK2/STAT3 pathway.

Area of Science:

  • Oncology
  • Pharmacology
  • Natural Products

Background:

  • Gastric cancer (GC) is a significant global health concern.
  • Berberine (BBR), a natural alkaloid, exhibits anti-cancer properties.
  • Understanding BBR's mechanism in GC is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the anti-cancer effects of Berberine (BBR) on gastric cancer (GC) cells.
  • To elucidate the underlying molecular mechanisms of BBR's action in GC.
  • To evaluate BBR's potential for gastric cancer prevention.

Main Methods:

  • In vitro assays: MTT, flow cytometry, scratch, and Transwell assays were used to assess proliferation, apoptosis, cell cycle arrest, migration, and invasion.
  • In vivo studies: Xenograft nude mouse models were employed to evaluate tumor growth inhibition.
  • Molecular analyses: RNA-Seq, qRT-PCR, Western Blot (WB), and ELISA were utilized to explore signaling pathways.

Main Results:

  • BBR inhibited proliferation and induced apoptosis and G0/G1 cell cycle arrest in MKN-45 and HGC-27 gastric cancer cells.
  • BBR suppressed gastric cancer cell migration and invasion in vitro and inhibited tumor growth in vivo.
  • RNA-Seq identified IL-6 as a key target, with BBR modulating the IL-6/JAK2/STAT3 signaling pathway.

Conclusions:

  • Berberine demonstrates significant anti-neoplastic effects against gastric cancer cells in vitro and in vivo.
  • BBR exerts its effects by targeting the IL-6/JAK2/STAT3 signaling pathway.
  • This study provides a scientific foundation for exploring BBR in gastric cancer prevention strategies.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K